These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 21241231)
1. The role of lipoprotein-associated phospholipase A2 (Lp-PLA₂) in cardiovascular disease. Ikonomidis I; Michalakeas CA; Lekakis J; Parissis J; Anastasiou-Nana M Rev Recent Clin Trials; 2011 May; 6(2):108-13. PubMed ID: 21241231 [TBL] [Abstract][Full Text] [Related]
2. Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events. Nambi V; Ballantyne CM Curr Atheroscler Rep; 2006 Sep; 8(5):374-81. PubMed ID: 16901407 [TBL] [Abstract][Full Text] [Related]
3. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Corson MA; Jones PH; Davidson MH Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target? Ahmed MS; Ji JZ; Meng QH Inflamm Allergy Drug Targets; 2011 Aug; 10(4):236-46. PubMed ID: 21539512 [TBL] [Abstract][Full Text] [Related]
6. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. Rosenson RS; Stafforini DM J Lipid Res; 2012 Sep; 53(9):1767-82. PubMed ID: 22665167 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Vittos O; Toana B; Vittos A; Moldoveanu E Biomarkers; 2012 Jun; 17(4):289-302. PubMed ID: 22401038 [TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Macphee C; Benson GM; Shi Y; Zalewski A Expert Opin Investig Drugs; 2005 Jun; 14(6):671-9. PubMed ID: 16004595 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Madjid M; Ali M; Willerson JT Tex Heart Inst J; 2010; 37(1):25-39. PubMed ID: 20200624 [TBL] [Abstract][Full Text] [Related]
10. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease. Epps KC; Wilensky RL J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587 [TBL] [Abstract][Full Text] [Related]
12. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
13. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?]. Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk? Lee JH; Engler MM Prog Cardiovasc Nurs; 2009 Dec; 24(4):181-9. PubMed ID: 20002343 [TBL] [Abstract][Full Text] [Related]
15. [Role of secreted and lipoprotein-associated phospholipase A2 in cardiovascular risk]. Ferri N; Corsini A G Ital Cardiol (Rome); 2014 Dec; 15(12):664-9. PubMed ID: 25533115 [TBL] [Abstract][Full Text] [Related]
16. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Cai A; Zheng D; Qiu R; Mai W; Zhou Y Dis Markers; 2013; 34(5):323-31. PubMed ID: 23478277 [TBL] [Abstract][Full Text] [Related]
17. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Lavi S; Herrmann J; Lavi R; McConnell JP; Lerman LO; Lerman A Curr Atheroscler Rep; 2008 Jun; 10(3):230-5. PubMed ID: 18489851 [TBL] [Abstract][Full Text] [Related]
18. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. Dullaart RP; Constantinides A; Perton FG; van Leeuwen JJ; van Pelt JL; de Vries R; van Tol A J Clin Endocrinol Metab; 2011 Apr; 96(4):1077-84. PubMed ID: 21252249 [TBL] [Abstract][Full Text] [Related]
19. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676 [TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Anderson JL Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]